Alliance for Pandemic Preparedness

October 7, 2020

An In-Depth Investigation of the Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine

Category:

Topic:

Keywords (Tags):

  • [Pre-print, not peer-reviewed] Administration of two inoculations of an inactivated SARS-CoV-2 vaccine was evaluated as safe and immunogenic in a phase I study in China. A double-blinded trial randomly assigned 192 healthy adults to receive one of the three doses of the vaccine or the placebo at an interval of 14 days or 28 days. Compared to the placebo group, the seroconversion rates of the neutralizing antibodies in the low-, medium- and high-dose groups reached 92%, 100% and 96% at day 14, and reached 80%, 96% and 92% at day 28, respectively. There were no abnormal variations in the serum samples of immunized subjects, and no severe adverse reactions were observed.

Pu et al. (Oct 6, 2020). An In-Depth Investigation of the Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine. Pre-print downloaded Oct 7 from https://doi.org/10.1101/2020.09.27.20189548